Back to the full story11 sources · STAT+: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more◆ Analytics
STAT+: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
Deterministic text analytics computed across all 11 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
cancerpancreaticdrugapprovesdaraxonrasibapprovedchemotherapytreatmentadvancedpatients
Top phrases
pancreatic cancerpancreatic cancer drugcancer drugfda approvesadvanced pancreatic canceradvanced pancreaticdaraxonrasib livedextending treatment for advanced pancreatictreatment for advanced pancreatic cancerlife extending treatment for advanced
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- FDA · 5 sources
- Drug Administration · 2 sources
- Patients · 2 sources
- The Food · 2 sources
- University · 2 sources
Unique to one source
- STAT · STAT
- Pharmalittle · STAT
- We’re · STAT
- Companies · The New York Times — Business
- Cincinnati Cancer Center · WLWT
- Boston · WCVB
- Chicago · NBC Chicago
- Ben Sasse · WOWT
- Omaha · WOWT
- Pancreatic · Scientific American
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "The FDA approved a life-extending treatment for advanced pancreatic cancer from Revolution Medicines that is the first to attack a genetic cause Good morning, everyone, and how are you today?" · STAT
- "We are doing just fine, thank you, despite the soggy weather hovering over the Pharmalot campus right now, because our spirits remain sunny, nonetheless." · STAT
- "Companies are testing dozens of similar drugs in cancers of the pancreas, lung, colon and more." · The New York Times — Business
- "The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer." · ABC7 Los Angeles
- "Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed." · CBS News — Top
- "In a large-scale clinical trial, people taking daraxonrasib lived twice as long as those given standard chemotherapy." · Gizmodo
- "In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy." · The New York Times — Business
- "Pancreatic cancer is considered one of the hardest to treat and most serious forms of cancer Pancreatic cancer is considered one of the hardest to treat and most serious forms of cancer" · Scientific American